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Increases in thrombin activity in patients given fibrinelytic agents
for
acute myocarial infarction have been shown to be important
in limiting the ultimate memos
of coronary thrombolysis . The
present study was designed to determine whether increases in
thrombin activity reflect, in part, activation of prothrombin
attvmpanying thrambolysis. Plmma concentrations of prothrom-
Mn fragmeni 1
.2, a pdyveptide released when prothrambin is
activated by radar Xa, were measured in 22 patients with state
myocmdia efantion hdare and after treatment with 100 mg of
ricanbinaml tisane.typa plasmimtgen activator ( rt.PA ). Ceneen.
trallens of prothrambles fragment 1 .2 increased front 0
.93 ±
L1 nU (mean m SD) before in-PA Infusion to 1.5 a 1 .5 11Af 2 h
alter initiation of the infusion (p < 0.05). After a 5,000-U
The role of persistent thrombin activity in inducing immedi-
ate or delayed thrombotic reocelusion in patients with myo-
cardial infarction treated with fibrinelytic agents is now
appreciated (1-3) .
However, mechanisms responsible for
increases in thrombin activity accompanying thrombolysis
have not been completely defined . We have shown that
thrombin activity increases in vitro in response to activation
of plasminogen with streptokinase or tissue-type plasmino-
gen activator (rt-PA) as a consequence of plasmin-mediated
activation of the coagulation system (6). In addition, throm-
bin bound to fibrin during formation of clots remains active
and may be exposed in clots undergoing lysis, promoting
continued fibrin formation, platelet activation and activation
of the coagulation system (7,5). Lysis of clot may expose
other procoagulahe factors, such as tissue factor in the
subendothelium, which can induce activation of the coagu-
lation system . Although several pharmacologic strategies to
inhibit coagulation during thrombalysis are possible,
selec-
tion
of optimal conjunctive anticoagulant regimens would be
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intravenous dose of heparin gives at the end of the infusion of
rt-PA, concentrations of prothrambin fragment 1,2 decreased
from 1 .9 ± 1 .5 to 1 .1 S 0.9 nM (e = n, p < 0.95), alaatgh
values .era silo
ixaeened
.moored oritln e.nmno a4oas herare
re-PA.
These results indicate that 4hross to activity increases in
patients given rl-PA at least in part become or odlvaWn of the
soagalation system leading l
. activation
of p.atremais. Tuns,
inhihhlonofthemaddoes levo ioncoagntantprvtehstbatkidto
activation of prothrnmbit stay be of vrdae as rmgnnelve treat-
ment to potentiate tat emncy of pinto acolegir thromsN'ML
(J Am Cad CaM1997 ;19.10Q5-9)
facilitated by knowledge of the mechanisms responsible for
increased proeoagutaot activity during t rombolysis (9).
In patients given streptokinase or rt-PA without concur-
rent intravenous heparin, plasma concentrations of Abrino-
peptide A. a marker of thrombin activity, increase markedly
(4,10). Increases in the concentration of fihrinopeptide A are
smaller when patients treated with libcinolytic agents are
given concurrent heparin, consistent with the inhibition of
thrombin by heparin (I1) .
Although increases in fihrino-
peptide A reflect increased thrombin activity, the extent to
which such increases ate attributable to new elaboration of
thrombin, as opposed to activity of prefor en d thrombin
exposed during thrombolysis, cannot be determined by
measurement of fibrinopeptide A . Recently, Gages et al . (5)
found that the concentration of thrombin-antithrombin lit
complexes increased in plasma of patients treated with
rt-PA, consistent with an increase in the amount of thrombin
available for inhibition by aJlithrombin ill, However, the
extent to which these results reflect activation of the coag-
ulation system alt
consequent activation of prollrombin
has not been defined. Because inhibition of earlier steps in
the coagulation pathway that lead to activation of prothrom-
bin may he
mere efficient than inhibition of thrombin in
attenuating procoagulant activity, we sought to define, the
extent of prothrombin activation in patients treated wish
rt-PA for acute myocardial infarction by measuring changes
in the plasma concentration of the prothro robin fragment 1 .2,
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by factor Xa . Factor Xa cleaves the pndhrombia molecule, releas-
ing prothrombin fragment 1 .2 and forming the active enzyme,
thrombin, a two-chain molecule . Activity of factor Xe toward
prothrombin is
greatly increased when Xe is associated on phaspho-
lipid membranes with its cofactor . activated factor V (VaN181 .
a poly peptide that is released when thrombin is formed
(12,13) (Fig . 11 .
Methods
Study patients . Twenty-two patients with acute myocar-
dial infarction who were admitted to the Cardiac Care Unit
of Barnes Hospital at Washington University Medical Cen-
ter and treated with rt-PA (Alteplase, Genentech) were
studied_ The decision to treat patients with r! -PA was batted
on clinical criteria, which generally included the presence of
at least 0
.1 mV of ST segment elevation in two aua[omically
contiguous leads on the admission electrocardiogram . Ex-
clusion criteria were those accepted to be contraindications
to the administration of fibrinolytic agents (141 . Adminisara-
lion of rt-PA was initiated with a 6-mg bolus followed by an
additional 54
mg
over the Ist h : then 40 mg was given over
2 h as a 20-mg)h infusion . In all but two patients, heparin was
given as a 5,000-U intravenous bolus at the end of the Ft-PA
in€union followed by a 1,000-U1h continuous infusion . [n two
patients, heparin was given before the start of the rt-PA
infusion as a 5,000-U intravenous bolus followed by a
LOW-UIh intravenous infusion . Subsequently . the dosage of
heparin was adjusted to maintain the activated partial throm-
boplastin time at 2 to 2.5 times that in control plasma . This
study was approved by the Human Studies Committee at
Washington University School of Medicine .
Acquisition of blood samples. Blood samples were ob-
tained from participants on their admission to the cardiac
care unit
. They were obtained by venipuncture except
during the rt-PA infusion, when they were drawn through a
large bore heparin lock (18-gauge). Samples were obtained
before initiation of the rt-PA infusion and 2, 3 .4 and 8 h after
the start of the infusion . In some patients, additional samples
were obtained at I, 12 and 24 h after the start of rl-PA
infusion. All samples were drawn by specially trained tech-
nicians and cooled immediately to 4°C in an ice bath for
20 min
. Blood was drawn into collection tubes containing
EDTA, aprotinin (200-KIU final concentration), and
r .~~orsa
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D-phenviaianyl-L prolyl-L argiaine-chlorylmethylketane
IPPACK) al a final concentration in excess of 5 pct
la inhibit
both c-PA and thrombin . Playlet-poor plasma was prepared
by centrifugation of each sample at 1,500 g for 30 min . The
plasma was frozen at -20'C for <24 h and then at -705 C
until it was assayed- The procedures used for sample acqui-
sition and processing have been validated extensively in
previous studies (L 10,15) .
Assay of prothrombin fragment 1 .2. The enzyme-linked
immunasarhent assay (ELISA) for prothrombin fragment
1 .2 employed a recently developed monoclonal antibody that
is specific for an antigenic site on the prothrombin fragment
1
.2 molecule absent in native prothrombin (16).
The ELISA
reagents were provided by Baxter Diagnostics, Inc . Plasma
samples were incubated for 30 min in wells of a microliter
plate coated with the monoclonal antibody specific for
prothrombin fragment 1 .2 . The plate was washed twice, and
a second monoclonal antibody conjugated to horseradish
peroxidase that also recognizes prothrombin fragment 1 .2
was incubated on the plate for 10 min at room temperature .
After washing, the horseradish peroxidase substrate, 3 .3', 5 .
5' tetrametlylbenzidine, was added and color was subse-
quently intensified by addition of I N sulfuric acid . The
absorhance attributable to hydrnaysis of the substrate was
monitored al 450 nM in an automated microliter plate reader
(Thermobtax . Molecular Devices) . The concentration of
prolhramoin fragment 1 .2 in the plasma snmples was deter-
mined by comparison with concurrently run standards of
purified human prothrombin fragment 1 .2 . All samples were
run in duplicate . The normal range for concentrations of
prothrombin fragment 1 .2 in plasma with this assay is 0.3 to
1 .1 1 116). In samples obtained from healthy young non-
hospitalized volunteers and processed in our laboratory in a
manner identical to that used in the current study, concen-
trations of prothrombin fragment 1 .2 were found to be
somewhat lower, 0 .16 * 0.08 nM.
Statistical analysis . Data are expressed as mean values t
SD . Because values for the concentrations of prothrombin
fragment 1
.2 were not distributed normally, a log transfor,
mnation was used before data were analyzed statistically .
Values for the log concentration of prothrombin fragment 1 .2
were distributed normally after the transformation . Concen-
trations of prothrombin fragment 1 .2 at each time point of er
initiation of rt-PA were compared with those on admission
(before n-PA) with a two-tailed paired I test- Differences
were considered to be significant when the p values were
< 0.05 .
Resellts
Concentrations of prothrombin fragment 1
.2 i plasma.
The plasma concentrations were 0 .89 ± 1
.2 mV before
initiation of the infusiou of n-PA in the 20 palienes with acute
myocardial infarction not given early heparin
. In three
patients, the concentrations exceeded 1.0 nM. In the two
patients given heparin before rt-PA, the concentrations were
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Figure 2. Concentration of prothrombin fragment 1 .2 before and
after initiation of rt-PA infusion in 22 patients with acute myocardial
infarction . The box plot shows the range of values associated with
50% of the values (25th to 75th percentir:) at each time point : the
median ae eentrxnnn is indicated by the line in each box. The
concentrations for the lath and 90th percentiles are indicated by Pie
bore. The concentration of prothrombin fragment 1 .2 increased
significantly over admission values after initiation of the a-PA
infusions . Smaller increases occurred during the 2nd and 3rd h of the
rt-PA infusions. The concentrations of prothromhin fragment 1 .2
decreased significantly after initiation or heparin Infusion at the end
of the rt-PA infusions
. However, an iecrvasc in concentration of
prothrombin fragment 1
.2 compared with that at admission was
noted despite treatment with heparin for up to 6 h after initiation of
rt-PA.
0.15 and 0
.28 nM after heparin but before n-PA . Concentra-
tions of prothrombin fragment 1
.2 increased after initiation
of rt-PA for the group as a whole to a mean of 1 .5 ± 1 .5 nM
2 h after onset of the n-PA infusion (p < 0 .05 compared with
admission values) (Fig. 2) . Concentration of prothrombin
fragment 1 .2 increased over pre-rt-PA values in all but 4
patients
; in 10 patients concentrations of prothrombin frag-
ment 1 .2 increased twofold . More marked increases oc-
curred within the 1st h after the initiation of rt-PA infusion in
the 12 patients whose samples were available at that time
point (3 .4 ± 5.5 nM). In the two patients given a 5 .000-U
bolus of heparin before rt-PA followed by a continuous
heparin infusion of 1,000 U/h, the concentration of pro-
thrombin fragment 1 .2 increased only minimally from 0.15
and 0
.28 nM after heparin but before n-PA, to 0.3 and
0.39 nM 2 h after rt-PA .
Response to heparin . Twenty patients were given a
5,000-U intravenous bolus of heparin at the end of the rt-PA
infusion, followed by a continuous heparin infusion . In the
other two patients, heparin was given before
ti-PA.
The
concentration of prothrombin fragment 1 .2 decreased signif-
icantly in the patients who were given heparin after rt-PA,
from 1 .8
t
1.8 nM before heparin to 1
.1 ± 0 .87 nM 1 h after
Initiation of heparin (p = 0 .02). However, the concentration
of prothrombin fragment 1 .2 remained elevated compared
EtSENh .'.RG RT AL.
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with baseline values (1 .3 *- 1 .1 04), with values > 1 .2 nM in
10 patients while heparin was being infused at a time when
the activated partial thromboplastin time was greater than
twice control in all but one patient .
Discussion
Our results indicate that activation of prothromhin occurs
in patients with acute myocardial infarction treated with
n-PA, which appears to account at least in part for the
increased thrombin activity that has been documented to
accompany pharmacologic thrombolysis (1 .4,10) . In previ-
ous studies (15) we have shown that thrombin activity. as
reflected by changes in the concentrations of fibrinopeplide
A- does not increase in the first few hours after the onset of
acute myocardial infarction when patients are not treated
with fibrinolytic agents . Thus, the results of the current
study are consistent with the induction of procoagutant
activity by fibrinolytic agents
. Our results suggest that
conjunctive anticoagulant agents given to inhibit activation
of prothrombin may be of particular value in this setting and
underscore the importance of concomitant anticoagulation in
patients treated with rt-PA .
Mechanisms for activation of prothrombin during pbarma-
cologie thrombolysis. One potential mechanism underlying
the activation of prothrombin nccompanying thromholysis is
activation of factor V by plasmin, as shown by Lee and
Mann (17). Because activation of prothrombin by factor Xa
is markedly accelerated by factor Vu, increased concentra-
tions of Va induced by plasmin proteolysis could account for
an increased prothromhin activation
(I8) . Increased activa-
tion of prothrombin suggests that the activity of the factor
XalVa complex may be an important determinant of the
extent of thrombin activity induced by fibrinalytic agents.
Thus, inhibition of this complex may be an ideal target for
conjunctive anticoagulation in patients treated with fibrin-
olytic agents. The recent observation (19) that tick antico-
agulant protein, a specific inhibitor of factor Xa, prevents
reocclusion in experimental preparations of coronary throm-
holysis is consistent with this hypothesis . Because the
Xa/Va complex can activate many prothrombin molecules,
its inhibition may be more efficient than inhibition of throm-
bin in attenuating procoagulant effects accompanying throm-
bolysis.
Role of heparin in inhibiting activation of prothrombin
during thrombolysis. The extent to which procoagulant ac-
tivity increased in response to rt-PA in our study was
probably influenced by the decision to initiate heparin at the
end of the n-PA infusion in most patients . In the two patients
given heparin before rt-PA, increases in the concentration of
prothrombin fragment 1 .2 were considerably less marked
.
The lack of increase in prothrombin fragment 1
.2 in these
two patients suggests that heparin may prevent the activa-
tion of prothrombin induced by administration of rt-PA
.
These results are consistent with the results of previous
studies
(4,5) in which increased plasma concentrations of
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fibrinespeptide A and thrombin-antithrombin 111 complexes
accompanying treatment with rt-PA were found to be atren-
uated after initiation of intravenous heparin . Although the
results of the TAME-3 study (20) suggest that delaying the
initiation of heparin does not decrease the incidence of
potency of the infarct-related artery at 90 min after the onset
of treatment with raPA, increases in procoagulant activity
could adversely affect the persistence of patency . In addi-
tion, early increases in procoagulant activity could delay clot
lysis (even within the 90-min TAMI-3 observation period) ur
account, in part, for the lower incidence of patency evident
I to several days later in patients treated with rt-PA without
heparin (2,3)
.
The importance of inhibition of thrombin is
evident from recent results (21) in a dog model of coronary
thrombosis in which cuujunctive treatment with hirudin, a
potent antithrombin, accelerated coronary thrombolysis and
prevented reocclusion. One limitation in interpretation of
results of the present study is the possibility that the de>
cress".S in the concentration of prothrmhin fragment 1 .2 we
observed after initiation of heparin therapy, although statis-
tically significant, would have occurred even in the absence
of heparin .
Value of monitoring procoagulaul activity in patients
treated with Nbrinolytic agents. Although our study was not
specificaily designed to characterize the utility of monitoring
patients for procoagulant activity during thrombolytie ther-
apy, our results suggest [hat assay of prothrombin fragment
1 .2 may provide useful clinical information . Other studies
(1,4) have shown greater increases in the concentration of
fibrinopeptide A, a marker of thrombin activity, in patients
in whom reocclusion occurs after treatment with rl-PA or
streptokinase. Increases in the concentration of thrombin-
antithrnmbin III complexes, a measure of elaboration of
thrombin, also appear to identify patients in whom reperfu-
sion does not occur and those prone to reocclusion as wall
(5). Saner and Rosenberg (22) found that prothrombin frag-
ment 1 .2 is more sensitive than fibrinopeptide A as a marker
of thrombosis in patients with thromhntic disorders
.
Whether changes in the 0Oncentrntion of prothrombin frag-
mnnt 1
.2 will be of prognostic value in patients treated with
febrinalytic agents for myocardial infarction is net yet clear,
but the possibility appears likely, increases in the concen-
tration ofprothrombin fragment
1 .2 in plasma call occur with
very high concentrations of plasmin in plasma as a direct
result of proteolysis of prothrombin by plasmin (23.24) . In
addition, the specificity of antibodies used by others for
prothrombin fragment 1.2 may influence results and lead to
differences with respect to our observations, Nonetheless,
characterization of activation of prothrombin accompanying
thrombolysis may be of value clinically, particularly
if anti-
coagulant agents designed to inhibit Xa/Va complex activity
prove to be useful as conjunctive agents
.
Clinical implications. The finding that prothena.hin acti-
vation accompanies thrombolysis when heparin is not given
suggests that the increases in thrombin activity observed
previously are at least in part attributable to increased
IACC V .I. 0, No. 5
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elaboration of thrombin rather than simply the activity of
preformed thrombin associated with clots . Because activa-
tion of prothrombin reflects activity of the factor XadVa
complex, one implication of our data is that inhibition of
earlier steps in the coagulation cascade may be a useful
target for conjunctive anticoagulation in the setting of throm-
bolysis .
We appreciate the tech meal aeralaesn or Matthew Oh[endorf in performing
thovnrays . Carat Meet— RN krulliettmi ; Elk. V .I.
for prepadpg the manuscript and Ruth Engeame for edilodel assistance . The
Contribution moan Rua . PhD of Bailer Dmgtantes, [ne, wln provides the
asany kits, is appreciated .
References
I . Ersenberg PR, Sherrean LA. Rich M. et a1. Importance of continued
adlvnlinn of thrnmhin record by Ehdnnpcp,idc A to the r5icacy oy
It tnntbalycis. I Am Call Cardiol 1986:7:185-62.
2. BleichSID. NicholYIC.Sahumechcralt .Coakn Bull, 'rat . 11A,'1'eichman
SL . EdccLotheparin rot cucun,ry arterial patency char thrombolysis with
lutist plasminogen activator in ecate myocardial it ramtiun. Am 1 Cmdiol
199a,65i 1412-17 .
J. Hsin1, Ramih.n WP, Kin . or NS, Raberls R, CMrtman BR, Ruaa AM .
A comparison between heparin and low-dose aspirin as adjunctive Iher,
apy with tissue plasminogen activator for acute myocardial rnrmction .
N EntiJ Med 1990:323:1433-7 .
4. Rapelld H1, Kuemmerli H. Weirs M . near H, Haebedi A . Monilodng of
hbdngeneration during Ihrombolytic therapy of . .[. myocardial imam
Iron with re umbinant tissue-type plasminogen activator . Circulation
1989 ;79:989-9,
5. Onlba DC. Barthels M, Westho8-Block M, et al. Increased Hnombin
levels during thrombulytic therapy in acure myocardial inf Icon . Circu-
lation 1991 :83
:937-44.
6. Eisenberg PR, Miletich JP . Induction of marked thrombin activity by
pharmacologic concentrations of plasmrnogen activators in nonanlicrvey.
rioted whole blood . Thrtunb Res 1999 ;55 :631-41.
7. Francisi7W . Markbas RE lr, RnrlawGH. FIumck TM. f atrnynski nIM,
Martini 9J . Thrornhln activity of fibrin thrombi and salable plasmic
derivatives. J Lab Clin Med I983 :Ibb22n.3u .
8 . Weitz JI, Hudoba M, Masset D. Maraganere 1, Hirsdr 1 . Clm-bouad
thrombin is protected from inhibition by hepnrio-anhlbraenbin III but is
.aptible t . ioxlivaGun by antithrombin l11-independent i,Jtibitusx .
101. Invest 1990:86 :395-91 .
9Subel BE, Coronary thrombolysis; edimrial waview. Coronary Anon
Disease 1990:10.7 .
Io, Eisenherg PR, Sherman LA . talk, AS. Parodenic devotion ofhhristapep-
tide A : evidence for tronttnued thrombosis despite intensive ftbdnalysis,
1 Am Coll Conduit 1987tili"27-9 .
11 . 0wen 1. Priedman KID, Grossmon HA, Wtnins C, Berke AD, Powers ER .
Thsombulytic therapy Mill tissue plasmrnogen activator at st :epiakinase
induces [mnsreot thrombin activity . Blood 1989 ;72'.616-20.
12. Late HK, Roeenberg is, Beeler DL . Rosenberg RD. The iselntine and
charavurkation or n cpec[ne antibody population directed vita a the
pmlhrombin activation frogmems F2 and Fl + 2. 1 Bial Chem 1979 ;254 :
8751-fit .
11, Told
IN,
noes : HK, Late
HK, Roc.berg RD, Svedi . . .Fit. prahrom-
bin ketivotltn pathway utilising radiaimmunaussays for the fragment
F21FI + 2 ftagmeln and thrombin-antithrombin complex. Blood 198759
(1B6A7.
14 . ChesabrolH, Knattemd G. Ratted, R, el al. Thmmhnlysis in Myocardial
Intarctan ITIMI) Idol, phase I : a comparison hetweee imrevenoas tissue
plasmiaogen acrOmor and intravenous streplokrnase . Ciwuhetion aunt :
7a142-54.
15 . Ersanberg tR. Shurman LA, Schectman K. Force J. Sobel BE . fork, AS.
Fibrinrpeptide A: a marker of..it coronary thrombosis . Circulation
1995;71:912-8.
'9-16L09'11361 P01I9 -MK
,Apflwmd01401 w, 43¢0170090!gwolgj'Oy 01094001119)10011
	
ZE
-0903100000
u49ulu U0 0010lOpIE IWE110 901d pue vs5logwolyi
40410408u!m1a(v,a4 u! 5':uaae 1ap7cd!,us Vwr paleGwoa wgw~14
,!
.ue
Joa111095"9191 0(1 '=4~sI001.V
i9IN's -
V910901.1311ays011IZ
'9-159
:
9(686(010194mr)
-
100000101l9ptOJlw 11000w
ug9JIq
-4-N(
51100
pue
101¢400,0mauww5eld00141sn000. uowJo
S1SAlU91 o11H.L 11N1030 ~0LLVAIIN7g11011H1071d
6901IV 19 9H31IN3SIA
"91-119(10661 P0019
110010
7o.9o o 100puadop.l101100(010aq,
30
,00113071 lwpuodap-aiepns
I~(w00s0ugOP)(
.d
M1PIIH '435 401440
3W
w!a4s1N
'DA
40014
BI
'06IW.3C6E61 P^
0
19'O1W5^(d
aG A00! 0J u04qu:NmuewnqJ0vo;mn000 041DII
00014 '0J
001 -
LI
'811159'16611000019401(10•
18690!, 1I70710910]ugw0lg100d10J
1#5113)
A-, 10491000101W
paquyaw5zva ue]0 s0.~sva,00090a^_000flJad'lela8
4!S'O!4S-91
609017661 IAAY
5 '-NW MA DOW
"LI6iI III Idd-908'6861 ^^9e'I"a1
!J "pogo) uopea0ae wanu!n~sela3!'01
le°+ P 1100
000paz!wopve011'101rJp 009000lap
•S
9
08100(0
•fH 10do1 'OZ
-0000096
41001 u!gwo19100d Jo s!s51001ad H1 90001(19 'lid 9019000!3 'ti
'.009-1111(111
'Ll-LO60S9061 5711 gwvogl(V'd-1)
0leap00 ua8oun00(1ad61-anss4
pe asewgmn qpm paledw01-!%01d010dqu!gw01ylold )0 409000(01
Jo sutya Ie0ualay!p•5
Y 0J1ef '911 Ia4-S 'd[ 4091199 '9d
810900113
'9(
!ddnefi8~0461u0(101) -ml-30090(s!sogwmyl(000(00]^ppawp000add01
0000111 m40,00(00011
once siu,,wd pue uo!snpadoo and!ogwmyl
saoueyda0001!Q!yWe% mtaeJ apaauS 'y !gsngaVS•001(05'0 gnse1A '61
